NCT04294641 2026-01-23
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
National Institutes of Health Clinical Center (CC)
Puma Biotechnology, Inc.
New York City Health and Hospitals Corporation
National Cancer Institute (NCI)
British Columbia Cancer Agency
AstraZeneca
Technische Universität Dresden
National Cancer Institute (NCI)